Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110122, P.R. China.
104K class 87, The Second Clinical College, China Medical University, Shenyang, Liaoning 110122, P.R. China.
Int J Oncol. 2022 Oct;61(4). doi: 10.3892/ijo.2022.5407. Epub 2022 Aug 5.
Bile acids (BAs) are the major components of bile and products of cholesterol metabolism. Cholesterol is catalyzed by a variety of enzymes in the liver to form primary BAs, which are excreted into the intestine with bile, and secondary BAs are formed under the modification of the gut microbiota. Most of the BAs return to the liver via the portal vein, completing the process of enterohepatic circulation. BAs have an important role in the development of hepatocellular carcinoma (HCC), which may participate in the progression of HCC by recognizing receptors such as farnesoid X receptor (FXR) and mediating multiple downstream pathways. Certain BAs, such as ursodeoxycholic acid and obeticholic acid, were indicated to be able to delay liver injury and HCC progression. In the present review, the structure and function of BAs were introduced and the metabolism of BAs and the process of enterohepatic circulation were outlined. Furthermore, the mechanisms by which BAs participate in the development of HCC were summarized and possible strategies for targeting BAs and key sites of their metabolic processes to treat HCC were suggested.
胆汁酸(BAs)是胆汁的主要成分和胆固醇代谢的产物。胆固醇在肝脏中被多种酶催化形成初级 BAs,与胆汁一起被排泄到肠道,在肠道微生物群的修饰下形成次级 BAs。大多数 BAs 通过门静脉返回肝脏,完成肠肝循环过程。BAs 在肝细胞癌(HCC)的发展中起重要作用,可能通过识别法尼醇 X 受体(FXR)等受体并介导多种下游途径参与 HCC 的进展。某些 BAs,如熊去氧胆酸和奥贝胆酸,被证明能够延缓肝损伤和 HCC 的进展。在本综述中,介绍了 BAs 的结构和功能,并概述了 BAs 的代谢和肠肝循环过程。此外,总结了 BAs 参与 HCC 发展的机制,并提出了针对 BAs 及其代谢过程关键部位的可能治疗 HCC 的策略。